It's about time to write off high-growth tech stocks, Goldman warned, saying software carries the highest multiples since the tech bubble.Marketsread more
Iran will surpass the internationally agreed levels of its low-enriched uranium levels in 10 days, the country's atomic energy body said Monday.Politicsread more
Boeing said the airline industry will need 44,040 new commercial airplanes by 2038. The market value of those planes would reach $6.8 trillion, up from $6.49 trillion...Airlinesread more
Apple is reportedly building three new iPhones for 2020, including two with 5G. It may also slightly change the screen sizes of the new iPhones.Technologyread more
Sotheby's announces it has signed an agreement to be acquired by BidFair USA, a venture owned by art collector Patrick Drahi.Marketsread more
Overall, extortion by email is growing significantly, according to the FBI's Internet Crime Compliant Center (IC3). Last year, these complaints rose 242% to 51,146 reported...Technologyread more
In a 7-2 ruling, over dissents from Justices Ruth Bader Ginsburg and Neil Gorsuch, the justices affirmed the so-called "dual sovereignty" exception to the Constitution's...Politicsread more
Target's nationwide cash register meltdown over the weekend created more than $16 million in buzz on the internet from news reports and other social media mentions, according...Retailread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
The top court scrapped a ruling from the Oregon Court of Appeals in favor of the same-sex couple. The owners of the bakery, which refused the make the cake due to religious...Politicsread more
Boeing reached a deal with British Airways to provide parts for some of its plane's made by rival manufacturer Airbus, part of Boeing's push to grow its services business.Airlinesread more
Americans are increasingly in favor of more federal regulation to rein in drug prices, including letting the government negotiate directly with drugmakers for the Medicare program, according to a new survey from the Kaiser Family Foundation.
Yet the poll also found that respondents are leery of potential consequences.
About 90 percent respondents to the health tracking survey favor two measures proposed by the Trump administration: requiring drug companies to include list prices in their advertising and making it easier for generic drugs to come to market. Kaiser surveyed 1,440 adults from Feb. 14 through Feb. 24.
A large majority also want Washington to go further when it comes to drugs for Medicare patients. Eighty-six percent support allowing the government to negotiate drug prices for Medicare, with 90 percent of Democrats and 80 percent of Republicans favoring the measure.
There's much less consensus on direct negotiations in Washington. While House Democrats have introduced a bill requiring the Centers for Medicare and Medicaid Services to negotiate with drugmakers directly for Medicare Part D drug plans, opposition is strong among Republicans.
"I don't want the government negotiating," Sen. Chuck Grassley, R-Iowa, told CNBC, adding that he opposes the Trump administration's proposal to bring Medicare drug prices closer to those paid by other industrial countries by using an international price benchmark.
"I want (prices) negotiated in the free market — I want a willing buyer and a willing seller to make that decision," said Grassley, chairman of the Senate Finance Committee.
During the committee's drug price hearing last week, AbbVie CEO Richard Gonzalez admitted that American consumers pay higher prices than people in other countries for his company's flagship arthritis drug Humira, but he maintained that dramatically cutting prices in the United States would effectively limit the company's ability to fund innovation and research into new treatments.
"Our system is built around a variety of pricing, around the world, but that overall system supports our R&D model," Gonzalez said.
The panel's top Democrat, Sen. Ron Wyden of Oregon, had a withering rebuke for that argument.
"If lower prices would diminish R&D, why don't costly dividends? Why don't stock buybacks? Is the stock price more important than inventing the next miracle cure?" Widen asked.
But the potential for less innovation is an issue that resonates in the recent Kaiser tracking poll.
Support for price negotiation dropped from 86 percent to just 31 percent if government price negotiations could hurt research and development. Support dropped just as sharply when presented with the argument that it could lead to Medicare not covering some prescription drugs.
A decade ago, a similar question on a Kaiser tracking poll found that nearly 48 percent supported increased price regulations even if it might lead to less R&D.
In the current era when new immunotherapy drugs have led to greater success in treating some cancers, and there is a growing need for innovative treatments for diseases like Alzheimer's, Americans may be less willing to make that trade off. They just want Washington to find a way to make drugs now more affordable.